nodes	percent_of_prediction	percent_of_DWPC	metapath
Loperamide—ABCB1—Mitoxantrone—lymphatic system cancer	0.0787	0.206	CbGbCtD
Loperamide—CYP3A4—Cytarabine—lymphatic system cancer	0.0684	0.18	CbGbCtD
Loperamide—CYP3A4—Teniposide—lymphatic system cancer	0.0674	0.177	CbGbCtD
Loperamide—Abdominal colic—Vincristine—lymphatic system cancer	0.0589	0.0952	CcSEcCtD
Loperamide—ABCB1—Vincristine—lymphatic system cancer	0.0541	0.142	CbGbCtD
Loperamide—CYP3A4—Mitoxantrone—lymphatic system cancer	0.0471	0.124	CbGbCtD
Loperamide—Megacolon toxic—Methotrexate—lymphatic system cancer	0.0464	0.075	CcSEcCtD
Loperamide—ABCB1—Methotrexate—lymphatic system cancer	0.0328	0.086	CbGbCtD
Loperamide—CYP3A4—Vincristine—lymphatic system cancer	0.0324	0.0851	CbGbCtD
Loperamide—Megacolon—Methotrexate—lymphatic system cancer	0.0236	0.0381	CcSEcCtD
Loperamide—Ileus paralytic—Vincristine—lymphatic system cancer	0.0184	0.0298	CcSEcCtD
Loperamide—Altered state of consciousness—Vincristine—lymphatic system cancer	0.0173	0.0279	CcSEcCtD
Loperamide—Epigastric pain—Mitoxantrone—lymphatic system cancer	0.0161	0.026	CcSEcCtD
Loperamide—Dermatitis bullous—Mechlorethamine—lymphatic system cancer	0.0153	0.0247	CcSEcCtD
Loperamide—Abdominal cramps—Vincristine—lymphatic system cancer	0.0118	0.0191	CcSEcCtD
Loperamide—Ileus—Vincristine—lymphatic system cancer	0.0113	0.0182	CcSEcCtD
Loperamide—Erythema multiforme—Mechlorethamine—lymphatic system cancer	0.00957	0.0155	CcSEcCtD
Loperamide—Toxic epidermal necrolysis—Fludarabine—lymphatic system cancer	0.00853	0.0138	CcSEcCtD
Loperamide—Depressed level of consciousness—Carmustine—lymphatic system cancer	0.00807	0.013	CcSEcCtD
Loperamide—Unspecified disorder of skin and subcutaneous tissue—Mechlorethamine—lymphatic system cancer	0.00745	0.012	CcSEcCtD
Loperamide—Stevens-Johnson syndrome—Fludarabine—lymphatic system cancer	0.00724	0.0117	CcSEcCtD
Loperamide—Anaphylactic shock—Mechlorethamine—lymphatic system cancer	0.00719	0.0116	CcSEcCtD
Loperamide—Skin disorder—Mechlorethamine—lymphatic system cancer	0.00698	0.0113	CcSEcCtD
Loperamide—Erythema multiforme—Fludarabine—lymphatic system cancer	0.0062	0.01	CcSEcCtD
Loperamide—Anaphylactoid reaction—Mitoxantrone—lymphatic system cancer	0.00583	0.00941	CcSEcCtD
Loperamide—Urinary retention—Vincristine—lymphatic system cancer	0.00551	0.00889	CcSEcCtD
Loperamide—Hypersensitivity—Mechlorethamine—lymphatic system cancer	0.0053	0.00856	CcSEcCtD
Loperamide—Abdominal pain upper—Mitoxantrone—lymphatic system cancer	0.00515	0.00832	CcSEcCtD
Loperamide—Pruritus—Mechlorethamine—lymphatic system cancer	0.00509	0.00822	CcSEcCtD
Loperamide—Diarrhoea—Mechlorethamine—lymphatic system cancer	0.00492	0.00795	CcSEcCtD
Loperamide—Discomfort—Fludarabine—lymphatic system cancer	0.0048	0.00776	CcSEcCtD
Loperamide—Anaphylactic shock—Fludarabine—lymphatic system cancer	0.00466	0.00753	CcSEcCtD
Loperamide—Vomiting—Mechlorethamine—lymphatic system cancer	0.00457	0.00738	CcSEcCtD
Loperamide—Nervous system disorder—Fludarabine—lymphatic system cancer	0.00457	0.00738	CcSEcCtD
Loperamide—Rash—Mechlorethamine—lymphatic system cancer	0.00453	0.00732	CcSEcCtD
Loperamide—Dermatitis—Mechlorethamine—lymphatic system cancer	0.00453	0.00732	CcSEcCtD
Loperamide—Drowsiness—Mitoxantrone—lymphatic system cancer	0.00434	0.00702	CcSEcCtD
Loperamide—Gastrointestinal pain—Teniposide—lymphatic system cancer	0.00433	0.007	CcSEcCtD
Loperamide—Nausea—Mechlorethamine—lymphatic system cancer	0.00427	0.0069	CcSEcCtD
Loperamide—Urticaria—Teniposide—lymphatic system cancer	0.00421	0.0068	CcSEcCtD
Loperamide—Abdominal pain—Teniposide—lymphatic system cancer	0.00419	0.00677	CcSEcCtD
Loperamide—Dyspepsia—Fludarabine—lymphatic system cancer	0.0041	0.00662	CcSEcCtD
Loperamide—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	0.00402	0.0065	CcSEcCtD
Loperamide—Fatigue—Fludarabine—lymphatic system cancer	0.00402	0.00649	CcSEcCtD
Loperamide—Constipation—Fludarabine—lymphatic system cancer	0.00398	0.00644	CcSEcCtD
Loperamide—Urinary tract disorder—Vincristine—lymphatic system cancer	0.00396	0.00639	CcSEcCtD
Loperamide—Urethral disorder—Vincristine—lymphatic system cancer	0.00393	0.00634	CcSEcCtD
Loperamide—Hypersensitivity—Teniposide—lymphatic system cancer	0.0039	0.00631	CcSEcCtD
Loperamide—Asthenia—Teniposide—lymphatic system cancer	0.0038	0.00614	CcSEcCtD
Loperamide—Pruritus—Teniposide—lymphatic system cancer	0.00375	0.00606	CcSEcCtD
Loperamide—Depressed level of consciousness—Methotrexate—lymphatic system cancer	0.00374	0.00604	CcSEcCtD
Loperamide—Diarrhoea—Teniposide—lymphatic system cancer	0.00363	0.00586	CcSEcCtD
Loperamide—Discomfort—Bleomycin—lymphatic system cancer	0.00352	0.00569	CcSEcCtD
Loperamide—Hypersensitivity—Fludarabine—lymphatic system cancer	0.00343	0.00554	CcSEcCtD
Loperamide—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.00341	0.00552	CcSEcCtD
Loperamide—Vomiting—Teniposide—lymphatic system cancer	0.00337	0.00544	CcSEcCtD
Loperamide—Asthenia—Fludarabine—lymphatic system cancer	0.00334	0.0054	CcSEcCtD
Loperamide—Rash—Teniposide—lymphatic system cancer	0.00334	0.0054	CcSEcCtD
Loperamide—Dermatitis—Teniposide—lymphatic system cancer	0.00334	0.00539	CcSEcCtD
Loperamide—Headache—Teniposide—lymphatic system cancer	0.00332	0.00536	CcSEcCtD
Loperamide—Pruritus—Fludarabine—lymphatic system cancer	0.0033	0.00532	CcSEcCtD
Loperamide—Diarrhoea—Fludarabine—lymphatic system cancer	0.00319	0.00515	CcSEcCtD
Loperamide—Nausea—Teniposide—lymphatic system cancer	0.00315	0.00509	CcSEcCtD
Loperamide—Vomiting—Fludarabine—lymphatic system cancer	0.00296	0.00478	CcSEcCtD
Loperamide—Rash—Fludarabine—lymphatic system cancer	0.00294	0.00474	CcSEcCtD
Loperamide—Dermatitis—Fludarabine—lymphatic system cancer	0.00293	0.00474	CcSEcCtD
Loperamide—Headache—Fludarabine—lymphatic system cancer	0.00292	0.00471	CcSEcCtD
Loperamide—Anaphylactoid reaction—Methotrexate—lymphatic system cancer	0.0029	0.00469	CcSEcCtD
Loperamide—Discomfort—Mitoxantrone—lymphatic system cancer	0.00286	0.00461	CcSEcCtD
Loperamide—Anaphylactic shock—Vincristine—lymphatic system cancer	0.00285	0.0046	CcSEcCtD
Loperamide—Nervous system disorder—Vincristine—lymphatic system cancer	0.00279	0.00451	CcSEcCtD
Loperamide—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.00277	0.00448	CcSEcCtD
Loperamide—Nausea—Fludarabine—lymphatic system cancer	0.00277	0.00447	CcSEcCtD
Loperamide—Urticaria—Bleomycin—lymphatic system cancer	0.00271	0.00438	CcSEcCtD
Loperamide—Skin disorder—Mitoxantrone—lymphatic system cancer	0.00269	0.00435	CcSEcCtD
Loperamide—Somnolence—Carmustine—lymphatic system cancer	0.00265	0.00428	CcSEcCtD
Loperamide—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.00257	0.00416	CcSEcCtD
Loperamide—Constipation—Carmustine—lymphatic system cancer	0.00255	0.00412	CcSEcCtD
Loperamide—Toxic epidermal necrolysis—Methotrexate—lymphatic system cancer	0.00253	0.00409	CcSEcCtD
Loperamide—Hypersensitivity—Bleomycin—lymphatic system cancer	0.00252	0.00407	CcSEcCtD
Loperamide—Somnolence—Mitoxantrone—lymphatic system cancer	0.00246	0.00398	CcSEcCtD
Loperamide—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.00246	0.00397	CcSEcCtD
Loperamide—Fatigue—Vincristine—lymphatic system cancer	0.00245	0.00396	CcSEcCtD
Loperamide—Asthenia—Bleomycin—lymphatic system cancer	0.00245	0.00396	CcSEcCtD
Loperamide—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.00244	0.00394	CcSEcCtD
Loperamide—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.00244	0.00394	CcSEcCtD
Loperamide—Constipation—Vincristine—lymphatic system cancer	0.00243	0.00393	CcSEcCtD
Loperamide—Pruritus—Bleomycin—lymphatic system cancer	0.00242	0.0039	CcSEcCtD
Loperamide—Fatigue—Mitoxantrone—lymphatic system cancer	0.00239	0.00386	CcSEcCtD
Loperamide—Constipation—Mitoxantrone—lymphatic system cancer	0.00237	0.00383	CcSEcCtD
Loperamide—Abdominal pain—Carmustine—lymphatic system cancer	0.00236	0.00381	CcSEcCtD
Loperamide—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.00233	0.00376	CcSEcCtD
Loperamide—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.00227	0.00366	CcSEcCtD
Loperamide—Abdominal pain—Vincristine—lymphatic system cancer	0.00225	0.00363	CcSEcCtD
Loperamide—Urticaria—Mitoxantrone—lymphatic system cancer	0.0022	0.00356	CcSEcCtD
Loperamide—Hypersensitivity—Carmustine—lymphatic system cancer	0.0022	0.00355	CcSEcCtD
Loperamide—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.00219	0.00354	CcSEcCtD
Loperamide—Vomiting—Bleomycin—lymphatic system cancer	0.00217	0.00351	CcSEcCtD
Loperamide—Drowsiness—Methotrexate—lymphatic system cancer	0.00216	0.0035	CcSEcCtD
Loperamide—Rash—Bleomycin—lymphatic system cancer	0.00215	0.00348	CcSEcCtD
Loperamide—Dermatitis—Bleomycin—lymphatic system cancer	0.00215	0.00348	CcSEcCtD
Loperamide—Stevens-Johnson syndrome—Methotrexate—lymphatic system cancer	0.00215	0.00347	CcSEcCtD
Loperamide—Asthenia—Carmustine—lymphatic system cancer	0.00214	0.00346	CcSEcCtD
Loperamide—Hypersensitivity—Vincristine—lymphatic system cancer	0.0021	0.00339	CcSEcCtD
Loperamide—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.00204	0.0033	CcSEcCtD
Loperamide—Asthenia—Vincristine—lymphatic system cancer	0.00204	0.0033	CcSEcCtD
Loperamide—Diarrhoea—Carmustine—lymphatic system cancer	0.00204	0.0033	CcSEcCtD
Loperamide—Nausea—Bleomycin—lymphatic system cancer	0.00203	0.00328	CcSEcCtD
Loperamide—Asthenia—Mitoxantrone—lymphatic system cancer	0.00199	0.00321	CcSEcCtD
Loperamide—Dizziness—Carmustine—lymphatic system cancer	0.00197	0.00318	CcSEcCtD
Loperamide—Diarrhoea—Vincristine—lymphatic system cancer	0.00195	0.00315	CcSEcCtD
Loperamide—Urinary tract disorder—Methotrexate—lymphatic system cancer	0.00192	0.0031	CcSEcCtD
Loperamide—Urethral disorder—Methotrexate—lymphatic system cancer	0.0019	0.00308	CcSEcCtD
Loperamide—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.0019	0.00306	CcSEcCtD
Loperamide—Vomiting—Carmustine—lymphatic system cancer	0.0019	0.00306	CcSEcCtD
Loperamide—Dizziness—Vincristine—lymphatic system cancer	0.00188	0.00304	CcSEcCtD
Loperamide—Rash—Carmustine—lymphatic system cancer	0.00188	0.00304	CcSEcCtD
Loperamide—Dermatitis—Carmustine—lymphatic system cancer	0.00188	0.00303	CcSEcCtD
Loperamide—Headache—Carmustine—lymphatic system cancer	0.00187	0.00302	CcSEcCtD
Loperamide—Erythema multiforme—Methotrexate—lymphatic system cancer	0.00184	0.00297	CcSEcCtD
Loperamide—Vomiting—Vincristine—lymphatic system cancer	0.00181	0.00292	CcSEcCtD
Loperamide—Rash—Vincristine—lymphatic system cancer	0.00179	0.0029	CcSEcCtD
Loperamide—Dermatitis—Vincristine—lymphatic system cancer	0.00179	0.0029	CcSEcCtD
Loperamide—Headache—Vincristine—lymphatic system cancer	0.00178	0.00288	CcSEcCtD
Loperamide—Nausea—Carmustine—lymphatic system cancer	0.00177	0.00286	CcSEcCtD
Loperamide—Vomiting—Mitoxantrone—lymphatic system cancer	0.00176	0.00285	CcSEcCtD
Loperamide—Immune system disorder—Methotrexate—lymphatic system cancer	0.00176	0.00284	CcSEcCtD
Loperamide—Rash—Mitoxantrone—lymphatic system cancer	0.00175	0.00282	CcSEcCtD
Loperamide—Dermatitis—Mitoxantrone—lymphatic system cancer	0.00175	0.00282	CcSEcCtD
Loperamide—Headache—Mitoxantrone—lymphatic system cancer	0.00174	0.0028	CcSEcCtD
Loperamide—Nausea—Vincristine—lymphatic system cancer	0.00169	0.00273	CcSEcCtD
Loperamide—Nausea—Mitoxantrone—lymphatic system cancer	0.00165	0.00266	CcSEcCtD
Loperamide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.00143	0.00231	CcSEcCtD
Loperamide—Discomfort—Methotrexate—lymphatic system cancer	0.00142	0.0023	CcSEcCtD
Loperamide—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.00138	0.00223	CcSEcCtD
Loperamide—Nervous system disorder—Methotrexate—lymphatic system cancer	0.00135	0.00219	CcSEcCtD
Loperamide—Skin disorder—Methotrexate—lymphatic system cancer	0.00134	0.00217	CcSEcCtD
Loperamide—Somnolence—Methotrexate—lymphatic system cancer	0.00123	0.00198	CcSEcCtD
Loperamide—Dyspepsia—Methotrexate—lymphatic system cancer	0.00122	0.00196	CcSEcCtD
Loperamide—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.00119	0.00193	CcSEcCtD
Loperamide—Fatigue—Methotrexate—lymphatic system cancer	0.00119	0.00192	CcSEcCtD
Loperamide—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.00113	0.00182	CcSEcCtD
Loperamide—Urticaria—Methotrexate—lymphatic system cancer	0.0011	0.00177	CcSEcCtD
Loperamide—Abdominal pain—Methotrexate—lymphatic system cancer	0.00109	0.00176	CcSEcCtD
Loperamide—Hypersensitivity—Methotrexate—lymphatic system cancer	0.00102	0.00164	CcSEcCtD
Loperamide—Asthenia—Methotrexate—lymphatic system cancer	0.000991	0.0016	CcSEcCtD
Loperamide—Pruritus—Methotrexate—lymphatic system cancer	0.000977	0.00158	CcSEcCtD
Loperamide—Diarrhoea—Methotrexate—lymphatic system cancer	0.000945	0.00153	CcSEcCtD
Loperamide—Dizziness—Methotrexate—lymphatic system cancer	0.000913	0.00148	CcSEcCtD
Loperamide—Vomiting—Methotrexate—lymphatic system cancer	0.000878	0.00142	CcSEcCtD
Loperamide—Rash—Methotrexate—lymphatic system cancer	0.000871	0.00141	CcSEcCtD
Loperamide—Dermatitis—Methotrexate—lymphatic system cancer	0.00087	0.00141	CcSEcCtD
Loperamide—Headache—Methotrexate—lymphatic system cancer	0.000865	0.0014	CcSEcCtD
Loperamide—Nausea—Methotrexate—lymphatic system cancer	0.00082	0.00133	CcSEcCtD
